Sanofi-aventis reveals “solid” financial performance

Sanofi-aventis has delivered a “solid” financial performance so far this year, it has stated.

The firm’s net sales for the timeframe reached 7,400 million euros (6.631 million pounds) ? an eight per cent growth rate on a reported basis from the same period of last year.

Net income for the first nine months of 2009 was 4,056 million euros, compared to 3,669 million euros for the first nine months of 2008.

Products that performed particularly well for the firm during this timeframe include Lovenox and Lantus, sales of which were up by 13.7 per cent and 21.7 per cent respectively.

Chief executive officer of the company Christopher Viehbacher commented: “We pursued our transformation strategy in the third quarter, reinforcing our platforms for growth and forging ahead with our policy of research and development alliances and targeted acquisitions.”

In other Sanofi-aventis news, the organisation announced last month that it plans to acquire the French biopharmaceutical ophthalmology company Fovea.